OGN Stock Analysis: Buy, Sell, or Hold?
OGN - Organon & Co.
$5.79
-0.05 (-0.94%)
▼
5d:
-5.01%
30d:
-20.64%
90d:
-19.43%
HOLD
LOW Confidence
Analysis Updated: Mar 27, 2026 12:00 AM ET
Earnings: May 07, 2026
Smart Money Accumulation
OGN is down 5.0% this week, but smart money is accumulating calls. Top strike: $7.5 2026-06-18 with 1,079 OI. Call ratio: 94% View Scanner →
Strength: 6.9/10
Get Alerted When OGN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: OGN shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: OGN shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$9.85
Based on 5.8% avg growth
INTRINSIC VALUE TODAY
$6.12
5.5% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 2.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: OGN is currently trading at $5.79, which is considered oversold relative to its 30-day fair value range of $6.02 to $7.35. From a valuation perspective, the stock is trading at a discount (Forward PE: 1.6) compared to its historical average (2.0). Remarkably, the market is currently pricing in an annual earnings decline of 7.0% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, OGN is in a downtrend. The price is currently testing key support at $5.76. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: OGN has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $9.00 (+54.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, OGN is in a downtrend. The price is currently testing key support at $5.76. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: OGN has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $9.00 (+54.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$6.02 -
$7.35
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
90.5%
Protect Your Profits
Holding OGN? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 54.1% below Wall St target ($9.00)
- CAUTION: Recommendation downgraded due to -5.0% 5-day decline
Fair Price Analysis
30-Day Fair Range
$6.02 -
$7.35
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$5.76
Resistance Level
$6.53
Current Trend
Downtrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
1.57
Wall Street Target
$9.00
(+54.1%)
Revenue Growth (YoY)
-5.3%
Earnings Growth (YoY)
-55.8%
Profit Margin
3.0%
Valuation Discount vs History
-7.0% cheaper
PE vs Historical
1.6 vs 2.0
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-7.0%
(market-implied from PE analysis)
1-Year Target
$5.43
(-7%)
2-Year Target
$5.05
(-14%)
3-Year Target
$4.70
(-20%)
3-Yr Target (if PE normalizes)
(PE: 2→2)
$6.00
(+3%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.4, Growth: 7.5%)
$103.68
(+1675%)
Base:
(SPY PE: 1.6, Growth: 7.5%)
$7.25
(+24%)
Bear:
(PE: 1.3, Growth: 7.5%)
$6.17
(+6%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (8x PE), but valuation improves significantly next year (2x PE) as earnings recover.
Trailing PE: 8.38 | Current EPS (TTM): $0.72
Bull Case
$13.27
(+118%)
Analyst growth 100.0%, PE expands to 9.2
Base Case
$12.06
(+98%)
Market implied 100.0%, PE stable at 8.4
Bear Case
$4.10
(-33%)
Severe decline -20.0%, PE contracts to 7.1
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 1.6 to 2.0
Stabilization Target:
$7.45
(+27.6%)
PE Expansion Potential:
+27.6%
Share & Embed Analysis
Last updated: March 30, 2026 12:18 PM ET
Data refreshes hourly during market hours. Next update: 1:18 PM
Data refreshes hourly during market hours. Next update: 1:18 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is OGN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
29 analysts |
$1209 | 51 HOLD |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$157 | 57 HOLD |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$206 | 62 BUY |
|
MRK
Merck & Company Inc |
BUY
26 analysts |
$128 | 68 BUY |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$351 | 58 HOLD |
Advanced OGN Option Strategies
Professional options setups generated by AI based on today's OGN price and gamma walls.
